**Core Concept**
The Philadelphia chromosome is a chromosomal abnormality resulting from a reciprocal translocation between chromosomes 9 and 22, leading to the creation of a BCR-ABL fusion gene. This genetic mutation is a hallmark of certain hematological malignancies.

**Why the Correct Answer is Right**
The Philadelphia chromosome is strongly associated with chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). The BCR-ABL fusion protein has tyrosine kinase activity, leading to uncontrolled cell proliferation and survival. Patients with the Philadelphia chromosome in CML have a worse prognosis due to the development of resistance to tyrosine kinase inhibitors and the likelihood of transformation to a more aggressive blast crisis.

**Why Each Wrong Option is Incorrect**
**Option A:** The Philadelphia chromosome is not a hallmark of acute myeloid leukemia (AML), which is a distinct entity from CML and ALL.
**Option B:** While the Philadelphia chromosome is associated with some cases of ALL, it is not a defining feature of the disease.
**Option C:** The Philadelphia chromosome is not a prognostic indicator in lymphoma, which is a separate category of hematological malignancies.

**Clinical Pearl / High-Yield Fact**
Remember that the presence of the Philadelphia chromosome in CML patients is a strong predictor of disease progression and resistance to therapy. This knowledge can guide treatment decisions and improve patient outcomes.

**Correct Answer: C. Acute Lymphoblastic Leukemia (ALL)**